RFA: Leukemia Exploration and Prevention Grant Program (LEAP)
Funds research into mechanisms and prevention strategies for leukemia in people with RUNX1 familial platelet disorder to accelerate cancer interception and therapy development.
Funder: American Cancer Society
Due Dates: June 1, 2026 (Full application submission for LEAP RFA)
Funding Amounts: Up to $215,000/year (RSG) or $430,000/year (Team Award) in direct costs for up to 4 years, plus 10% indirects; max $946,000 (RSG) or $1,892,000 (Team) total.
Summary: Supports research on mechanisms and prevention strategies for leukemia in patients with RUNX1 familial platelet disorder to accelerate cancer interception and therapy development.
Key Information: Applicants may submit only one application per cycle and must be full-time independent investigators at eligible US institutions.
Description
The Leukemia Exploration and Prevention (LEAP) Grant Program, a collaboration between the American Cancer Society and the RUNX1 Research Program, funds investigator-initiated research to advance understanding and prevention of leukemia in individuals with RUNX1 familial platelet disorder (RUNX1-FPD). The program aims to address critical knowledge gaps in leukemogenic progression and to enable translational research that identifies actionable targets, biomarkers, or interventions for cancer interception or prevention in this high-risk population. Two main research focus areas are supported: (1) elucidating mechanisms underlying leukemogenic progression in germline RUNX1-mutated hematopoietic stem/progenitor cells (including both cell-autonomous and cell-nonautonomous factors), and (2) translational research to develop or validate preventive or interceptive strategies for RUNX1-FPD-related cancers.
